Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,669,812,908.04, representing a year-on-year increase of 25.42% compared to CNY 1,324,581,073.87 in the same period last year[3]. - The net profit attributable to shareholders of the listed company was CNY 45,688,589.04, a slight increase of 1.59% from CNY 44,588,853.42 in the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 77.02% to CNY 41,375,154.29 from CNY 23,629,646.82 in the same period last year[3]. - The company reported a basic earnings per share of CNY 0.05, unchanged from the previous year[4]. - The total comprehensive income for the first quarter of 2023 was CNY 47,414,780.36, an increase from CNY 46,090,528.29 in the same period of 2022, representing a growth of approximately 2.86%[16]. Cash Flow - The net cash flow from operating activities increased by 92.05% to CNY 130,889,329.27, compared to CNY 68,459,009.16 in the previous year[4]. - The net cash flow from operating activities for Q1 2023 was CNY 130,889,329.27, significantly higher than CNY 68,153,420.75 in Q1 2022, indicating an increase of about 92.4%[18]. - The total cash inflow from financing activities was CNY 697,270,082.10 in Q1 2023, compared to CNY 228,329,538.31 in Q1 2022, reflecting a substantial increase of approximately 205.5%[19]. - The net cash flow from financing activities for Q1 2023 was -CNY 137,996,819.86, worsening from -CNY 9,018,694.18 in Q1 2022[19]. - The cash and cash equivalents at the end of Q1 2023 stood at CNY 323,314,673.48, down from CNY 395,130,807.40 at the end of Q1 2022, a decrease of about 18.2%[19]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 8,548,945,159.23, a decrease of 2.50% from CNY 8,727,665,447.53 at the end of the previous year[4]. - Current liabilities decreased to ¥3,526,689,113.33 from ¥4,129,057,002.94, representing a reduction of 14.6%[12]. - The total liabilities decreased to ¥4,979,764,208.53 from ¥5,220,496,898.35, a decline of 4.6%[13]. - Long-term borrowings increased to ¥1,236,885,323.06 from ¥867,176,000.00, indicating a rise of 42.5%[12]. Shareholder Information - The company has 116,523 common shareholders as of the end of the reporting period[8]. - The top shareholder, Hualu Holdings Group Co., Ltd., holds 20.91% of the shares, totaling 185,896,620 shares[8]. Research and Development - Research and development expenses increased to ¥72,066,772.99 in Q1 2023, compared to ¥60,176,722.79 in Q1 2022, marking a rise of 19.7%[15]. Inventory and Expenses - Inventory as of March 31, 2023, was ¥1,503,632,882.92, slightly up from ¥1,480,685,151.67 at the end of 2022[12]. - The cash paid for purchasing goods and services in Q1 2023 was CNY 635,306,475.83, down from CNY 741,247,430.29 in Q1 2022, representing a decrease of about 14.3%[18]. - The company received CNY 18,184,609.68 in tax refunds during Q1 2023, compared to CNY 23,881,168.78 in Q1 2022, a decline of approximately 23.9%[18]. - The company incurred cash outflows of CNY 73,776,345.22 for taxes in Q1 2023, which is significantly higher than CNY 27,151,145.58 in Q1 2022, an increase of about 171.5%[18]. Acquisition - The company acquired a 60% stake in Shandong Rukang Zhonghe Environmental Technology Co., Ltd. for CNY 62.0659 million, which was completed on August 24, 2022, and is now a wholly-owned subsidiary[4].
鲁抗医药(600789) - 2023 Q1 - 季度财报